Thus, in order to abolish the high expression levels of Bcl-xL reported in many cancers, Bcl-x SSOs were designed to induce a splicing switch, favoring the production of the pro-apoptotic isoform Bcl-xS. This evidence concerns the gene BCL2L1 and cancer.